Clofazimine

Last updated

Clofazimine
Clofazimine.svg
Clofazimine 3D spacefill.png
Clinical data
Trade names Lamprene
Other namesN,5-bis(4-chlorophenyl)-3-(1-methylethylimino)-5H-phenazin-2-amine
AHFS/Drugs.com Monograph
MedlinePlus a682128
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life 70 days
Identifiers
  • N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.016.347 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C27H22Cl2N4
Molar mass 473.40 g·mol−1
3D model (JSmol)
Melting point 210 to 212 °C (410 to 414 °F)
  • CC(C)/N=c/1\cc-2n(c3ccccc3nc2cc1Nc4ccc(cc4)Cl)c5ccc(cc5)Cl
  • InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3 X mark.svgN
  • Key:WDQPAMHFFCXSNU-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Clofazimine, sold under the brand name Lamprene, is a medication used together with rifampicin and dapsone to treat leprosy. [1] It is specifically used for multibacillary (MB) leprosy and erythema nodosum leprosum. [2] Evidence is insufficient to support its use in other conditions [1] though a retrospective study found it 95% effective in the treatment of Mycobacterium avium complex (MAC) when administered with a macrolide and ethambutol, [3] as well as the drugs amikacin and clarithromycin. [4] However, in the United States, clofazimine is considered an orphan drug, is unavailable in pharmacies, and its use in the treatment of MAC is overseen by the Food and Drug Administration. [5] It is taken orally. [1]

Contents

Common side effects include abdominal pain, diarrhea, itchiness, dry skin, and change in skin color. [1] It can also cause swelling of the lining of the gastrointestinal tract, increased blood sugar, and sensitivity to the sun. [2] It is unclear if use during pregnancy is safe. [1] Clofazimine is a phenazine dye and is believed to work by interfering with DNA. [1]

Clofazimine was discovered in the 1950s at Trinity College, Dublin, [6] and approved for medical use in the United States in 1986. [1] It is on the World Health Organization's List of Essential Medicines. [7] In the United States it is not available commercially but can be obtained from the US Department of Health and Human Services. [1]

Medical uses

The primary use of clofazimine is for the treatment of leprosy. [1] Other uses have not been proven to be safe or effective. [1]

It has been studied in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in people with HIV/AIDS and Mycobacterium avium paratuberculosis . Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum (ENL). (From AMA Drug Evaluations Annual, 1993, p1619). The drug is given as an alternative to people who can not tolerate the effects of dapsone for leprosy. [8]

Early research suggested clofazimine inhibits the replication of SARS-CoV-2 in vitro and reduce viral load and inflammation in the lung in animal models [9]

Side effects

Clofazimine produces pink to brownish skin pigmentation in 75-100% of patients within a few weeks, as well as similar discoloration of most bodily fluids and secretions. These discolorations are reversible but may take months to years to disappear. There is evidence in medical literature that as a result of clofazimine administration, several patients have developed depression which in some cases resulted in suicide. It has been hypothesized that the depression was a result of this chronic skin discoloration. [10]

Cases of ichthyosis and skin dryness are also reported in response to this drug (8%-28%), as well as rash and itchiness (1-5%).[ medical citation needed ]

Mechanism

Clofazimine works by binding to the guanine bases of bacterial DNA, thereby blocking the template function of the DNA and inhibiting bacterial proliferation. [11] [12] It also increases activity of bacterial phospholipase A2, leading to release and accumulation of lysophospholipids, [11] [12] which are toxic and inhibit bacterial proliferation. [13] [14]

Clofazimine is also a FIASMA (functional inhibitor of acid sphingomyelinase). [15]

Metabolism

Clofazimine has a biological half life of about 70 days. Autopsies performed on those who have died while on clofazimine show crystal-like aggregates in the intestinal mucosa, liver, spleen, and lymph nodes. [16]

History

Clofazimine, initially known as B663, was first synthesised in 1954 by a team of scientists at Trinity College, Dublin: Frank Winder, J.G. Belton, Stanley McElhinney, M.L. Conalty, Seán O'Sullivan, and Dermot Twomey, led by Vincent Barry. Clofazimine was originally intended as an anti-tuberculosis drug but proved ineffective. In 1959, a researcher named Y. T. Chang identified its effectiveness against leprosy. After clinical trials in Nigeria and elsewhere during the 1960s, Swiss pharmaceutical company Novartis launched the product in 1969 under the brand name Lamprene.[ citation needed ]

Novartis was granted FDA approval of clofazimine in December 1986 as an orphan drug. The drug is currently no longer commercially available in the United States as Novartis has discontinued production of clofazimine for the US market and no generic or other brand names are marketed in the US although it retains FDA approval. [17]

Society and culture

Clofazimine is marketed under the trade name Lamprene by Novartis although its discontinued in some countries like the US. Other brands are also available in many countries. Another producer of the clofazimine molecule is Sangrose Laboratories, located in Mavelikara, India.[ citation needed ]

Research

The immunosuppressive effects of clofazimine were immediately noticed when applied in animal model. Macrophages were first reported to be inhibited due to the stabilization of lysosomal membrane by clofazimine. [18] Clofazimine also showed a dosage-dependent inhibition of neutrophil motility, lymphocyte transformation, [19] mitogen-induced PBMC proliferation [20] and complement-mediated solubilization of pre-formed immune complexes in vitro. [21] A mechanistic studying of clofazimine in human T cells revealed that this drug is a Kv1.3 (KCNA3) channel blocker. [22] This indicates that clofazimine will be potentially used for treatment of multiple sclerosis, rheumatoid arthritis and type 1 diabetes. Because the Kv1.3-high effector memory T cells (TEM) are actively involved in the development of these diseases, [23] and Kv1.3 activity is essential for stimulation and proliferation of TEM by regulating calcium influx in the T cells. [24] Several clinical trials were also conducted looking for its immunosuppressive activity even before it was approved for leprosy by FDA. It was first reported to be effective in treating chronic discoid lupus erythematosus with 17 out of 26 patients got remission. [25] But later another group found it was ineffective in treating diffuse, photosensitive, systemic lupus erythematosus. [26] Clofazimine also has been sporadically reported with some success in other autoimmune diseases such as psoriasis, [27] Miescher's granulomatous cheilitis. [28]

Related Research Articles

<span class="mw-page-title-main">Minocycline</span> Antibiotic medication

Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic medication used to treat a number of bacterial infections such as some occurring in certain forms of pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis. It is taken by mouth or applied to the skin.

<span class="mw-page-title-main">Immunosuppressive drug</span> Drug that inhibits activity of immune system

Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications, are drugs that inhibit or prevent the activity of the immune system.

<i>Mycobacterium</i> Genus of bacteria

Mycobacterium is a genus of over 190 species in the phylum Actinomycetota, assigned its own family, Mycobacteriaceae. This genus includes pathogens known to cause serious diseases in mammals, including tuberculosis and leprosy in humans. The Greek prefix myco- means 'fungus', alluding to this genus' mold-like colony surfaces. Since this genus has cell walls with a waxy lipid-rich outer layer containing high concentrations of mycolic acid, acid-fast staining is used to emphasize their resistance to acids, compared to other cell types.

<i>Mycobacterium leprae</i> Bacterium that causes leprosy

Mycobacterium leprae is one of the two species of bacteria that cause Hansen's disease (leprosy), a chronic but curable infectious disease that damages the peripheral nerves and targets the skin, eyes, nose, and muscles.

<span class="mw-page-title-main">Dapsone</span> Antibiotic medication

Dapsone, also known as 4,4'-sulfonyldianiline (SDA) or diaminodiphenyl sulfone (DDS), is an antibiotic commonly used in combination with rifampicin and clofazimine for the treatment of leprosy. It is a second-line medication for the treatment and prevention of pneumocystis pneumonia and for the prevention of toxoplasmosis in those who have poor immune function. Additionally, it has been used for acne, dermatitis herpetiformis, and various other skin conditions. Dapsone is available both topically and by mouth.

<span class="mw-page-title-main">Pimecrolimus</span> Immunosuppressive drug

Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema).

<span class="mw-page-title-main">Rifampicin</span> Antibiotic medication

Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires' disease. It is almost always used together with other antibiotics with two notable exceptions: when given as a "preferred treatment that is strongly recommended" for latent TB infection; and when used as post-exposure prophylaxis to prevent Haemophilus influenzae type b and meningococcal disease in people who have been exposed to those bacteria. Before treating a person for a long period of time, measurements of liver enzymes and blood counts are recommended. Rifampicin may be given either by mouth or intravenously.

<span class="mw-page-title-main">Mepacrine</span> Medication

Mepacrine, also called quinacrine or by the trade names Atabrine or Atebrin, is a medication with several uses. It is related to chloroquine and mefloquine. Although available from compounding pharmacies, as of August 2020 approved formulations are not available in the United States.

<span class="mw-page-title-main">Penicillamine</span> Chemical compound

Penicillamine, sold under the brand name of Cuprimine among others, is a medication primarily used for the treatment of Wilson's disease. It is also used for people with kidney stones who have high urine cystine levels, rheumatoid arthritis, and various heavy metal poisonings. It is taken by mouth.

<span class="mw-page-title-main">Lupus vulgaris</span> Painful facial skin nodules due to infection by M. tuberculosis

Lupus vulgaris are painful cutaneous tuberculosis skin lesions with nodular appearance, most often on the face around the nose, eyelids, lips, cheeks, ears and neck. It is the most common Mycobacterium tuberculosis skin infection. The lesions may ultimately develop into disfiguring skin ulcers if left untreated.

<i>Mycobacterium avium-intracellulare</i> infection Medical condition

Mycobacterium avium-intracellulare infection (MAI) is an atypical mycobacterial infection, i.e. one with nontuberculous mycobacteria or NTM, caused by Mycobacterium avium complex (MAC), which is made of two Mycobacterium species, M. avium and M. intracellulare. This infection causes respiratory illness in birds, pigs, and humans, especially in immunocompromised people. In the later stages of AIDS, it can be very severe. It usually first presents as a persistent cough. It is typically treated with a series of three antibiotics for a period of at least six months.

<span class="mw-page-title-main">Belimumab</span> Pharmaceutical drug

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.

<span class="mw-page-title-main">KCNA3</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel, shaker-related subfamily, member 3, also known as KCNA3 or Kv1.3, is a protein that in humans is encoded by the KCNA3 gene.

<span class="mw-page-title-main">Lupus erythematosus</span> Collection of human autoimmune diseases

Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs. The most common and most severe form is systemic lupus erythematosus.

A leprostatic agent is a drug that interferes with proliferation of the bacterium that causes leprosy.

Tumid lupus erythematosus is a rare, but distinctive entity in which patients present with edematous erythematous plaque.

Palisaded neutrophilic and granulomatous dermatitis (PNGS) is usually associated with a well-defined connective tissue disease, lupus erythematosus or rheumatoid arthritis most commonly, and often presents with eroded or ulcerated symmetrically distributed umbilicated papules or nodules on the elbows.

<span class="mw-page-title-main">Lupus</span> Autoimmune disease in which the immune system attacks healthy tissue

Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Children up to 18 years old develop a more severe form of SLE termed childhood-onset systemic lupus erythematosus.

Blisibimod is a selective antagonist of B-cell activating factor, being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.

<span class="mw-page-title-main">Promin</span> Chemical compound

Promin, or sodium glucosulfone is a sulfone drug that was investigated for the treatment of malaria, tuberculosis and leprosy. It is broken down in the body to dapsone, which is the therapeutic form.

References

  1. 1 2 3 4 5 6 7 8 9 10 "Clofazimine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  2. 1 2 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 132. hdl: 10665/44053 . ISBN   9789241547659.
  3. ↑ Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA (May 2016). "Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin". Chest. 149 (5): 1285–1293. doi:10.1378/chest.15-0543. PMID   26513209.
  4. ↑ Ferro BE, Meletiadis J, Wattenberg M, de Jong A, van Soolingen D, Mouton JW, et al. (February 2016). "Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin". Antimicrobial Agents and Chemotherapy. 60 (2): 1097–1105. doi:10.1128/aac.02615-15. PMC   4750661 . PMID   26643335.
  5. ↑ "Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) | Clinical Research Trial Listing ( Mycobacterium avium Complex | MAC Infection (Mycobacterium Avium Complex) | Mycobacterium avium-intracellulare Infection ) ( NCT02968212 )". Archived from the original on 2022-09-13. Retrieved 2020-11-11.
  6. ↑ Greenwood D (2008). Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. OUP Oxford. p. 200. ISBN   9780199534845. By 1954 related molecules known as iminophenazines were being investigated... one of the first ones to be made, originally given the laboratory code B663 ... B663—subsequently called clofazimine
  7. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ↑ Clinical Microbiology Made Ridiculously Simple
  9. ↑ Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, et al. (May 2021). "Clofazimine broadly inhibits coronaviruses including SARS-CoV-2". Nature. 593 (7859): 418–423. Bibcode:2021Natur.593..418Y. doi: 10.1038/s41586-021-03431-4 . PMC   7553155 . PMID   33727703. S2CID   232262689.
  10. ↑ Brown S (1998). Psychiatric Side Effects of Prescription and Over-the-counter Medications: Recognition and Management. American Psychiatric Pub. ISBN   9780880488686. Archived from the original on 2016-03-05.
  11. 1 2 Arbiser JL, Moschella SL (February 1995). "Clofazimine: a review of its medical uses and mechanisms of action". Journal of the American Academy of Dermatology. 32 (2 Pt 1): 241–247. doi:10.1016/0190-9622(95)90134-5. PMID   7829710.
  12. 1 2 Morrison NE, Marley GM (1976). "The mode of action of clofazimine DNA binding studies". International Journal of Leprosy and Other Mycobacterial Diseases. 44 (1–2): 133–134. PMID   945233.
  13. ↑ Dennis, E. A. 1983. Phospholipases, p. 307-353. In P. D. Boyer (ed.), The enzymes, 3rd ed., vol. 16. Lipid enzymology. Academic Press, Inc., New York.
  14. ↑ Kagan VE (1989). "Tocopherol stabilizes membrane against phospholipase A, free fatty acids, and lysophospholipids". Annals of the New York Academy of Sciences. 570 (1): 121–135. Bibcode:1989NYASA.570..121K. doi:10.1111/j.1749-6632.1989.tb14913.x. PMID   2698101. S2CID   44638207.
  15. ↑ Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. (2011). "Identification of novel functional inhibitors of acid sphingomyelinase". PLOS ONE. 6 (8): e23852. Bibcode:2011PLoSO...623852K. doi: 10.1371/journal.pone.0023852 . PMC   3166082 . PMID   21909365.
  16. ↑ Baik J, Rosania GR (October 2011). "Molecular imaging of intracellular drug-membrane aggregate formation". Molecular Pharmaceutics. 8 (5): 1742–1749. doi:10.1021/mp200101b. PMC   3185106 . PMID   21800872.
  17. ↑ "Lamprene (clofazimine) dosing, indications, interactions, adverse effects, and more". Archived from the original on 2014-07-09. Retrieved 2014-06-13.
  18. ↑ Conalty ML, Barry VC, Jina A (Apr 1971). "The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system". International Journal of Leprosy and Other Mycobacterial Diseases. 39 (2): 479–492. PMID   4948088.
  19. ↑ Gatner EM, Anderson R, van Remsburg CE, Imkamp FM (June 1982). "The in vitro and in vivo effects of clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals". Leprosy Review. 53 (2): 85–90. doi: 10.5935/0305-7518.19820010 . PMID   7098757. S2CID   46460241.
  20. ↑ van Rensburg CE, Gatner EM, Imkamp FM, Anderson R (May 1982). "Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy". Antimicrobial Agents and Chemotherapy. 21 (5): 693–697. doi:10.1128/aac.21.5.693. PMC   181995 . PMID   7049077.
  21. ↑ Kashyap A, Sehgal VN, Sahu A, Saha K (February 1992). "Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes in vitro". International Journal of Immunopharmacology. 14 (2): 269–273. doi:10.1016/0192-0561(92)90039-N. PMID   1624226.
  22. ↑ Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. (Dec 2008). "Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes". PLOS ONE. 3 (12): e4009. Bibcode:2008PLoSO...3.4009R. doi: 10.1371/journal.pone.0004009 . PMC   2602975 . PMID   19104661.
  23. ↑ Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. (November 2006). "Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17414–17419. Bibcode:2006PNAS..10317414B. doi: 10.1073/pnas.0605136103 . PMC   1859943 . PMID   17088564.
  24. ↑ Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, et al. (June 2003). "The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS". The Journal of Clinical Investigation. 111 (11): 1703–1713. doi:10.1172/JCI16921. PMC   156104 . PMID   12782673.
  25. ↑ Mackey JP, Barnes J (July 1974). "Clofazimine in the treatment of discoid lupus erythematosus". The British Journal of Dermatology. 91 (1): 93–96. doi:10.1111/j.1365-2133.1974.tb06723.x. PMID   4851057. S2CID   43528153.
  26. ↑ Jakes JT, Dubois EL, Quismorio FP (November 1982). "Antileprosy drugs and lupus erythematosus". Annals of Internal Medicine. 97 (5): 788. doi:10.7326/0003-4819-97-5-788_2. PMID   7137755.
  27. ↑ Chuaprapaisilp T, Piamphongsant T (September 1978). "Treatment of pustular psoriasis with clofazimine". The British Journal of Dermatology. 99 (3): 303–305. doi:10.1111/j.1365-2133.1978.tb02001.x. PMID   708598. S2CID   36255192.
  28. ↑ Podmore P, Burrows D (March 1986). "Clofazimine--an effective treatment for Melkersson-Rosenthal syndrome or Miescher's cheilitis". Clinical and Experimental Dermatology. 11 (2): 173–178. doi:10.1111/j.1365-2230.1986.tb00443.x. PMID   3720016. S2CID   631224.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.